What are the recommended PET‑CT scan timings for a Hodgkin lymphoma patient receiving Nivolumab (240 mg) plus AVD (doxorubicin, vinblastine, dacarbazine) chemotherapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

PET Scan Timing for Hodgkin Lymphoma on Nivolumab-AVD Treatment

For patients receiving Nivolumab plus AVD (N-AVD) for Hodgkin lymphoma, perform interim PET-CT after 2 cycles of treatment and end-of-treatment PET-CT after completing all planned cycles.

Recommended PET-CT Schedule

Interim PET-CT (iPET)

  • Timing: After 2 cycles of N-AVD 1
  • This follows the established ABVD paradigm where interim PET after 2 cycles has proven prognostic value
  • The NIVAHL trial, which specifically evaluated N-AVD, performed interim staging after 2 cycles 2
  • Deauville score ≤3 indicates negative/favorable response; ≥4 indicates positive/unfavorable response 1

End-of-Treatment PET-CT

  • Timing: 3-8 weeks after completing all planned cycles 1, 3
  • Optimal timing is 6-8 weeks post-treatment to minimize false-positives from inflammatory changes 3
  • Minimum wait of 3 weeks is acceptable if earlier assessment is clinically necessary 3

Clinical Context for N-AVD

The evidence base for PET timing in N-AVD comes from extrapolation of ABVD protocols combined with specific N-AVD trial data:

NIVAHL Trial Experience 2:

  • Patients received either 4 cycles of concomitant N-AVD or sequential nivolumab followed by N-AVD
  • Interim staging occurred after 2 cycles of N-AVD (concomitant arm) or after 4 doses of nivolumab monotherapy (sequential arm)
  • 100% of concomitant N-AVD patients achieved objective response at interim PET
  • Final PET-CT was performed after completing all treatment

Older Adult N-AVD Study 4:

  • Patients received 6 cycles of N-AVD
  • PET-2 (after 2 cycles) was performed but was NOT predictive of progression-free survival or overall survival in this cohort
  • This suggests that while interim PET should still be performed per standard protocols, treatment decisions in N-AVD may rely less heavily on interim results than with ABVD alone

Important Caveats

Timing Considerations

  • Avoid PET within 2 weeks of chemotherapy to reduce false-positives from acute inflammation 3
  • Avoid PET within 2-3 months of radiation therapy if RT is part of the treatment plan 3
  • Growth factor administration can cause increased bone marrow uptake for up to 10 days 5

Interpretation Differences

Unlike ABVD where positive interim PET (Deauville ≥3-4) typically prompts treatment escalation 1, the role of treatment modification based on interim PET in N-AVD is less established. The NIVAHL trial showed excellent outcomes regardless of interim PET results 2, and the older adult study found PET-2 non-predictive 4.

Standard vs. N-AVD Protocols

Traditional ABVD guidelines recommend:

  • Interim PET after 2 cycles for advanced-stage disease 1
  • Treatment intensification (e.g., switch to BEACOPPescalated) for positive interim PET 1

However, with N-AVD, continue the planned regimen even if interim PET is positive, as the addition of nivolumab appears to overcome the negative prognostic significance of interim PET positivity seen with ABVD alone 2, 4.

Practical Algorithm

  1. Baseline PET-CT: Before starting N-AVD
  2. After Cycle 2: Interim PET-CT (iPET2)
    • Document Deauville score
    • Continue N-AVD regardless of result (unlike ABVD protocols)
  3. After completing planned cycles: End-of-treatment PET-CT
    • Wait 6-8 weeks if possible (minimum 3 weeks)
    • Defines final response status

This approach balances established PET-adapted strategies from ABVD trials with emerging evidence that N-AVD may not require the same response-adapted modifications.

Related Questions

Is it appropriate to perform an interim PET‑CT scan in patients receiving Nivolumab (240 mg IV) plus AVD (doxorubicin 25 mg/m², vinblastine 6 mg/m², dacarbazine 375 mg/m²) chemotherapy?
When Opdivo (nivolumab) and Adriamycin (doxorubicin) are given together, should Opdivo be administered first?
A 51-year-old male with classic Hodgkin lymphoma and a bulky anterior mediastinal mass received six cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). End-of‑treatment PET‑CT shows a residual mass with Deauville score 4, and biopsy confirms persistent disease. What is the next appropriate treatment?
How should I assess and manage a patient with relapsed nodular‑sclerosing Hodgkin lymphoma, confirmed by biopsy, who now has new FDG‑avid lymphadenopathy below the diaphragm on PET/CT after completing six cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy?
What are the standard doses and recommended adjustments for the ABVD regimen (doxorubicin, bleomycin, vinblastine, dacarbazine) in Hodgkin lymphoma?
What were the design, dosing regimen, and outcomes of the NRG‑GY018 phase III trial evaluating pembrolizumab (Keytruda) combined with carboplatin‑paclitaxel chemotherapy in patients with advanced (stage III–IVB) or recurrent endometrial carcinoma?
What antipyretic medication is appropriate for a patient with liver failure who has a fever?
Can losartan (angiotensin II receptor blocker) cause xerostomia and decreased appetite?
What is the drug of choice for antiepileptic therapy in a patient with chronic kidney disease on maintenance hemodialysis who also has chronic liver disease?
How should semaglutide be initiated and titrated in a patient with type 2 diabetes mellitus and proliferative diabetic retinopathy?
What is the appropriate naproxen dosing regimen for an adult with osteoarthritis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.